Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2015-08-19 Share Issue/Capital Cha…
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Share Issue/Capital Change 2015
Share Issue/Capital Change Classification · 99% confidence The document explicitly announces a 'Capital Increase in Genmab as a Result of Employee Warrant Exercise'. It details the number of shares issued, the subscription prices, the total proceeds (DKK 120.9 million), and the resulting change in the company's cash position guidance. This content directly relates to changes in the company's capital structure and fundraising activities resulting from the exercise of employee stock options/warrants. This aligns perfectly with the definition for 'Capital/Financing Update' (Code: CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a general regulatory filing (RNS), as it concerns a specific, material capital event.
2015-08-19 English
Share Issue/Capital Change 2015
Share Issue/Capital Change Classification · 99% confidence The document is titled 'Company Announcement' and details a specific corporate action: an increase in share capital resulting from the exercise of employee warrants. It specifies the number of shares issued, the subscription prices, the total proceeds, and the impact on the company's cash position and share capital amount. This directly relates to changes in the company's capital structure and financing activities. This aligns perfectly with the definition for 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a dividend notice (DIV).
2015-08-19 English
Director's Dealing 2015
Director's Dealing Classification · 99% confidence The document explicitly states it is a 'Company Announcement' made 'Pursuant to Section 28a of the Danish Securities Trading Act' and details transactions involving shares by a managerial employee (President & Chief Executive Officer) and their related parties. This content directly matches the definition of a Director's Dealing report, which covers personal share transactions by company directors and executives (insider trades). The corresponding code is DIRS.
2015-08-14 English
Director's Dealing 2015
Director's Dealing Classification · 99% confidence The document is titled 'Selskabsmeddelelse' (Company Announcement) and explicitly reports on transactions involving shares by a leading employee ('ledende medarbejdere') and their related parties, citing the Danish Securities Trading Act (§ 28a). The content details the name (Jan van de Winkel), position (President & CEO), transaction type (Sale), and number/value of shares traded. This directly corresponds to the definition of Director's Dealing or insider trade reporting. The appropriate code is DIRS.
2015-08-14 Danish
M&A Activity 2015
M&A Activity Classification · 99% confidence The document starts with the header "Selskabsmeddelelse" (Company Announcement) and details a specific business transaction: Genmab granting commercial licenses to Novo Nordisk for the DuoBody technology, including upfront payments and potential milestone/royalty payments. This is a specific corporate action announcement, not a comprehensive annual report (10-K), quarterly report (IR), earnings release (ER), or a general regulatory filing (RNS). It relates to a strategic partnership and financing terms, which aligns best with the Capital/Financing Update (CAP) category, as it involves licensing fees and future financial considerations tied to development. However, since it is a specific announcement about a commercial agreement and technology licensing, it is often categorized under general regulatory announcements if a more specific category like M&A (TAR) doesn't apply. Given the options, this is a material corporate event announcement. It is not a standard earnings release, management discussion, or proxy material. Since it involves a significant commercial agreement and potential future payments, it is a material event announcement. In many regulatory contexts, such specific, non-financial-result-focused announcements that are material to the business fall under general regulatory disclosures. Given the provided definitions, it is a material announcement that doesn't fit perfectly into the financial report categories. It is most closely related to a general regulatory announcement or a financing/capital event. Since it details a licensing deal structure (upfront payment, milestones), 'CAP' (Capital/Financing Update) is plausible, but 'RNS' (Regulatory Filings) is the safest fallback for specific, non-standard corporate news releases in Danish format ('Selskabsmeddelelse'). Given the nature of the announcement (licensing deal structure), I will classify it as a general Regulatory Filing (RNS) as it is a material, non-periodic disclosure.
2015-08-14 Danish
M&A Activity 2015
M&A Activity Classification · 99% confidence The document is titled 'Company Announcement' and details a specific business transaction: the granting of commercial licenses by Genmab to Novo Nordisk, including upfront payments and potential milestones. This type of announcement, which details strategic business deals, financing terms, or significant corporate events outside of routine financial reporting (like 10-K or ER), often falls under general regulatory announcements or specific transaction categories. Since it involves a licensing agreement and associated financial considerations (upfront payment, milestones), it relates to capital structure changes or financing activities. However, it is not a formal filing like a 10-K, an earnings release (ER), or a proxy statement. It is a general corporate update. Given the options, 'Capital/Financing Update' (CAP) fits well as it describes a significant financial agreement. Alternatively, 'Regulatory Filings' (RNS) is a broad fallback. Since the core content is a licensing deal with financial terms, CAP is the most specific fit among the provided definitions, as it relates to financing activities and capital generation through partnerships. It is not a Director's Dealing (DIRS), a Dividend Notice (DIV), or a Major Shareholding Notification (MRQ).
2015-08-14 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.